Retrospective Study
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Jul 24, 2022; 13(7): 652-662
Published online Jul 24, 2022. doi: 10.5306/wjco.v13.i7.652
Assessing radiation dose for postoperative radiotherapy in prostate cancer: Real world data
Asunción Hervás-Morón, Jose Domínguez-Rullán, Victor Duque Santana, Mireia Valero, Carmen Vallejo, Sonsoles Sancho, Juan David García Fuentes, Miguel Cámara Gallego, Fernando López-Campos
Asunción Hervás-Morón, Jose Domínguez-Rullán, Victor Duque Santana, Mireia Valero, Carmen Vallejo, Sonsoles Sancho, Fernando López-Campos, Department of Radiation Oncology, Hospital Universitario Ramón Y Cajal, Madrid 28034, Spain
Juan David García Fuentes, Miguel Cámara Gallego, Department of Medical Physics, Hospital Universitario Ramón Y Cajal, Madrid 28034, Spain
Author contributions: Hervás A, Domínguez-Rullán JA, Duque Santana V, Valero M, Vallejo C, Sancho S, García Fuentes JD, Cámara Gallego M and López-Campos F contributed to writing, review, editing and supervision; all authors have read and approve the final manuscript.
Institutional review board statement: The study was reviewed and approved by the Ethics Research Committee of Hospital Universitario Ramón y Cajal.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: The manuscript has been read and approved for submission by all the named authors. All authors declare no conflict of interests for this article.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Fernando López-Campos, MD, PhD, Professor, Department of Radiation Oncology, Hospital Universitario Ramón Y Cajal, Carretera de Colmenar Viejo Km 9100, Madrid 28034, Spain. fernando_lopez_campos@hotmail.com
Received: March 27, 2022
Peer-review started: March 27, 2022
First decision: May 12, 2022
Revised: June 4, 2022
Accepted: July 5, 2022
Article in press: July 5, 2022
Published online: July 24, 2022
Processing time: 116 Days and 16.2 Hours
Core Tip

Core Tip: This retrospective study was performed to evaluate whether higher doses of postoperative radiotherapy influence biochemical failure-free survival rates in patients with prostate cancer. Our results show no significant differences in biochemical failure-free survival, cancer-specific survival, metastasis-free survival, or overall survival regardless of the radiotherapy dose (66-68 vs 70 vs 72 Gy). No differences in treatment-related toxicity were observed. These findings suggest that radiation dose intensification is not superior to conventional radiotherapy treatment.